Future Science Group
Browse

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 Phase III study design. Supplementary Material

Download (76.65 kB)
figure
posted on 2022-01-26, 10:22 authored by Neeraj Agarwal, Arun Azad, Neal D. Shore, Joan Carles, André P. Fay, Curtis Dunshee, Lawrence Ivan Karsh, Maria Luisa Paccagnella, Nicola Di Santo, Mohamed Elmeliegy, Xun Lin, Akos Czibere, Karim Fizazi

Supplementary Figure 1- Study locations of TALAPRO-2

Supplementary Methods - DDR alteration analysis

Infographic – Summary of the TALAPRO-2 study

Funding

Pfizer

History

Usage metrics

    Future Oncology

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC